Loading...
XNAS
IART
Market cap1.43bUSD
Jul 10, Last price  
18.79USD
1D
6.30%
1Q
85.76%
Jan 2017
-57.13%
Name

Integra Lifesciences Holdings Corp

Chart & Performance

D1W1MN
XNAS:IART chart
P/E
P/S
0.89
EPS
Div Yield, %
Shrs. gr., 5y
-2.07%
Rev. gr., 5y
3.57%
Revenues
1.64b
+1.53%
419,297,000550,459,000654,604,000682,487,000732,068,000780,078,000830,871,000836,214,000928,305,000882,734,000992,075,0001,188,236,0001,472,441,0001,517,557,0001,371,868,0001,542,448,0001,557,666,0001,541,573,0001,610,527,0001,635,245,000
Net income
-516m
L+7,337.70%
29,407,00033,471,00034,933,00050,955,00065,669,00027,989,00041,204,000-16,977,00034,004,000-3,519,00074,564,00064,743,00060,801,00050,201,000133,892,000169,075,000180,550,00067,741,000-6,944,000-516,474,000
CFO
50m
-61.06%
71,702,00047,026,00072,590,000143,235,000105,571,000104,328,00058,715,00053,268,00079,463,00094,483,000116,405,000114,544,000199,683,000231,433,000203,832,000312,427,000264,469,000139,955,000129,382,00050,384,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
IPO date
Aug 16, 1995
Employees
3,722
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT